Clinical trial
Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors
NCT00003198 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003198 |
|---|---|
| Title | Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors |
| Official title | A Phase I Dose-Escalation Study of Topotecan and Ifosfamide in Patients With Refractory Non-Hematologic Malignancies. |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | ifosfamide, topotecan hydrochloride |
| Start date | Nov 1, 1997 |
| Primary completion | May 1, 2000 |
| Completion | May 1, 2000 |
| First posted | Jul 8, 2004 |
| Last update posted | Jun 27, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: